4,772 reports of this reaction
3.1% of all PEMBROLIZUMAB reports
#4 most reported adverse reaction
FATIGUE is the #4 most commonly reported adverse reaction for PEMBROLIZUMAB, manufactured by Merck Sharp & Dohme LLC. There are 4,772 FDA adverse event reports linking PEMBROLIZUMAB to FATIGUE. This represents approximately 3.1% of all 152,954 adverse event reports for this drug.
PEMBROLIZUMAB has an overall safety score of 88 out of 100. Patients taking PEMBROLIZUMAB who experience fatigue should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
FATIGUE is moderately reported among PEMBROLIZUMAB users, representing a notable but not dominant share of adverse events.
In addition to fatigue, the following adverse reactions have been reported for PEMBROLIZUMAB:
The following drugs have also been linked to fatigue in FDA adverse event reports:
FATIGUE has been reported as an adverse event in 4,772 FDA reports for PEMBROLIZUMAB. This does not prove causation, but indicates an association observed in post-market surveillance data.
FATIGUE accounts for approximately 3.1% of all adverse event reports for PEMBROLIZUMAB, making it a notable side effect.
If you experience fatigue while taking PEMBROLIZUMAB, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.